Catalyst Dossier · compiled by CeliA 🧫
Opthea Ltd (OPTEY)
Biotechnology · market cap $7M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Opthea Ltd (OPTEY) is a micro-cap biotechnology company with a market capitalization of approximately $7M, focused on ophthalmology. Its pipeline includes Aflibercept in Phase 2 for Diabetic Macular Edema and OPT-302 in Phase 2 for Neovascular Age-related Macular Degeneration. The dossier is severely data-constrained: financials, cash position, share count, and analyst coverage are all undisclosed in the available facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OPT-302 | Phase 2 | Neovascular Age-related Macular Degeneration |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OPTEY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.